On Friday, Apogee Therapeutics Inc (NASDAQ: APGE) was -7.36% drop from the session before settling in for the closing price of $51.01. A 52-week range for APGE has been $16.39 – $72.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 10.37%. With a float of $36.11 million, this company’s outstanding shares have now reached $37.17 million.
In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Apogee Therapeutics Inc (APGE) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Apogee Therapeutics Inc stocks. The insider ownership of Apogee Therapeutics Inc is 38.26%, while institutional ownership is 80.62%. The most recent insider transaction that took place on Nov 06 ’24, was worth 394,041. In this transaction Chief Medical Officer of this company sold 6,665 shares at a rate of $59.12, taking the stock ownership to the 267,463 shares. Before that another transaction happened on Nov 06 ’24, when Company’s Chief Executive Officer sold 15,000 for $59.22, making the entire transaction worth $888,320. This insider now owns 1,339,487 shares in total.
Apogee Therapeutics Inc (APGE) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 10.37% per share during the next fiscal year.
Apogee Therapeutics Inc (NASDAQ: APGE) Trading Performance Indicators
You can see what Apogee Therapeutics Inc (APGE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 16.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.73, a number that is poised to hit -1.06 in the next quarter and is forecasted to reach -4.31 in one year’s time.
Technical Analysis of Apogee Therapeutics Inc (APGE)
Looking closely at Apogee Therapeutics Inc (NASDAQ: APGE), its last 5-days average volume was 0.42 million, which is a drop from its year-to-date volume of 0.49 million. As of the previous 9 days, the stock’s Stochastic %D was 10.76%. Additionally, its Average True Range was 3.64.
During the past 100 days, Apogee Therapeutics Inc’s (APGE) raw stochastic average was set at 39.59%, which indicates a significant increase from 4.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.94% in the past 14 days, which was higher than the 57.31% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $54.78, while its 200-day Moving Average is $49.74. However, in the short run, Apogee Therapeutics Inc’s stock first resistance to watch stands at $50.12. Second resistance stands at $52.99. The third major resistance level sits at $54.85. If the price goes on to break the first support level at $45.39, it is likely to go to the next support level at $43.53. Now, if the price goes above the second support level, the third support stands at $40.66.
Apogee Therapeutics Inc (NASDAQ: APGE) Key Stats
There are 45,027K outstanding shares of the company, which has a market capitalization of 2.56 billion. As of now, sales total 0 K while income totals -83,990 K. Its latest quarter income was 0 K while its last quarter net income were -33,820 K.
